SMC2 and Miyoshi myopathy: These MM cells were treated with RGD-IONP/CAPE at different CAPE concentrations (0, 5, 10, 20 and 30 μM), CAPE alone (30 μM), non-targeted IONP/CAPE (30 μM), and RGD-IONP vehicle control.